Literature DB >> 9127015

C-C chemokines, IL-16, and soluble antiviral factor activity are increased in cloned T cells from subjects with long-term nonprogressive HIV infection.

E Scala1, G D'Offizi, R Rosso, O Turriziani, R Ferrara, A M Mazzone, G Antonelli, F Aiuti, R Paganelli.   

Abstract

A combination of three beta, or C-C, chemokines, as well as IL-16, have been shown to inhibit HIV replication in vitro. Cellular antiviral factor is a more potent agent, and acts on all HIV strains. All are mainly, but not exclusively, produced by CD8+ T cells, both in HIV+ and healthy subjects. We studied the production of these HIV-suppressive factors in patients with HIV infection at different stages of disease. No difference in production by PBMC stimulated with PHA has been observed in asymptomatic HIV+, long-term nonprogressors (LTnP), and AIDS patients. When T cell line supernatants from these three groups were studied, no significant difference was found for C-C chemokines or IL-16 production, and viral suppression. However, T cell clones from LTnP secreted higher levels of all three chemokines, IL-16, and exerted a stronger inhibition on HIV replication. CD8+ clones showed a higher production than CD4+ clones. These clones were able to produce all antiviral factors irrespective of the secretion of type 1 or type 2 cytokines. The antiviral activities were not correlated, implying that viral suppression did not depend solely on C-C chemokines or IL-16. We postulate that all factors are needed to prevent HIV disease progression.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9127015

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  19 in total

1.  Modulation of HIV transcription by CD8(+) cells is mediated via multiple elements of the long terminal repeat.

Authors:  D M Maslove; L W Ni; N C Hawley-Foss; A D Badley; K F Copeland
Journal:  Clin Exp Immunol       Date:  2001-07       Impact factor: 4.330

2.  Highly active antiretroviral therapy and beta-chemokines.

Authors:  B Brichacek; M Bukrinsky
Journal:  Clin Exp Immunol       Date:  2002-11       Impact factor: 4.330

Review 3.  The role of infant immune responses and genetic factors in preventing HIV-1 acquisition and disease progression.

Authors:  C Farquhar; G John-Stewart
Journal:  Clin Exp Immunol       Date:  2003-12       Impact factor: 4.330

Review 4.  The CD8+ T Cell Noncytotoxic Antiviral Responses.

Authors:  Maelig G Morvan; Fernando C Teque; Christopher P Locher; Jay A Levy
Journal:  Microbiol Mol Biol Rev       Date:  2021-05-12       Impact factor: 11.056

Review 5.  Chemokine receptors and chemokines in HIV infection.

Authors:  A Garzino-Demo; A L DeVico; R C Gallo
Journal:  J Clin Immunol       Date:  1998-07       Impact factor: 8.317

6.  Anti-feline immunodeficiency virus (FIV) soluble factor(s) produced from antigen-stimulated feline CD8(+) T lymphocytes suppresses FIV replication.

Authors:  I S Choi; R Hokanson; E W Collisson
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

7.  CD8+ T cell-mediated enhancement of tumour necrosis factor-alpha (TNF-alpha) production and HIV-1 LTR-driven gene expression in human monocytic cells is pertussis toxin-sensitive.

Authors:  K F Copeland; P J McKay; J Newton; K L Rosenthal
Journal:  Clin Exp Immunol       Date:  1999-06       Impact factor: 4.330

8.  Acute alcohol consumption attenuates interleukin-8 (IL-8) and monocyte chemoattractant peptide-1 (MCP-1) induction in response to ex vivo stimulation.

Authors:  G Szabo; S Chavan; P Mandrekar; D Catalano
Journal:  J Clin Immunol       Date:  1999-01       Impact factor: 8.317

9.  Binding of HIV-2 envelope glycoprotein to CD8 molecules and related chemokine production.

Authors:  H Akimoto; H Kaneko; I Sekigawa; H Hashimoto; Y Kaneko; N Yamamoto
Journal:  Immunology       Date:  1998-10       Impact factor: 7.397

10.  Stimulation of toll-like receptor 2 in mononuclear cells from HIV-infected patients induces chemokine responses: possible pathogenic consequences.

Authors:  L Heggelund; J K Damås; A Yndestad; A M Holm; F Mūller; E Lien; T Espevik; P Aukrust; S S Frøland
Journal:  Clin Exp Immunol       Date:  2004-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.